Krystal Biotech: The Rise of a Profitable Giant in Scalable Gene Therapy
Reading Time: 3 minutes
Validated Platform Revolution: With the world's first topical gene therapy VYJUVEK, Krystal Biotech has proven that its HSV-1 vector is safe, reliably dosable, and commercially highly profitable (96% gross margin). Scalability Beyond the Skin: Thanks to the new FDA "Platform Technology Designation," the company is accelerating its technology's expansion into lucrative billion-dollar markets such as pulmonary medicine (cystic fibrosis), ophthalmology, and aesthetic gene cosmetics by 2025. Krystal Biotech, Inc. represents the successful...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
